13F Holdings
中文EN

JSPR Jasper Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1788028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-73.0%
TTM EPS YoY184.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-153.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets14.2%
Debt / equity—
Current ratio10.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.31x
Accruals ratio-106.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
Cost of revenue$41.63M$34.27M———
R&D expense$63.10M$55.82M$51.78M$34.63M$25.42M
SG&A expense$20.78M$20.42M$17.08M$16.57M$11.41M
Operating income-$83.88M-$76.24M-$68.86M-$51.20M-$36.83M
Income tax—$2,000$2,000——
Net income-$75.80M-$71.27M-$64.47M-$37.69M-$30.64M
EBITDA-$82.83M-$74.87M-$67.75M-$50.22M-$36.46M
EPS (basic)-3.95-4.89-6.18-10.33-2.69
EPS (diluted)-3.95-4.89-6.18-10.33-2.69
Weighted avg. shares (diluted)19.17M14.58M10.44M3.65M11.39M
Banking
Net interest income——-$246,000-$115,000-$80,000
Balance sheet
Cash & equivalents$28.69M$72.05M$87.30M$38.67M$85.05M
Current assets$34.65M$75.81M$88.94M$41.73M$87.83M
PP&E, net$102,000$1.88M$2.73M$3.57M$3.69M
Total assets$35.78M$79.90M$94.89M$48.36M$93.65M
Current liabilities$13.20M$15.24M$12.37M$7.07M$8.02M
Total liabilities$31.63M$18.23M$16.45M$12.37M$24.14M
Shareholders' equity$4.15M$61.67M$78.44M$35.99M$69.52M
Shares outstanding933,24215.02M11.16M3.80M37.86M
Cash flow statement
Operating cash flow-$77.16M-$62.60M-$52.07M-$45.86M-$33.68M
Investing cash flow$5,000-$532,000-$267,000-$576,000-$2.43M
Financing cash flow$34.21M$47.88M$100.97M$55,000$100.97M
Depreciation & amortization$1.06M$1.37M$1.11M$975,000$377,000
Stock-based compensation$6.71M$6.62M$5.21M$4.09M$1.05M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.